AI summary by TwinMind
Natera ft. Matthew Rabinowitz - A Personal Mission That Led to a Biotech Revolution
Sequoia Capital
52m 55s
Company Overview & Personal Motivation
- Natera: global leader in women's health, oncology, organ transplant rejection testing
- 40% of US pregnancies tested using Natera technology
- Nearly half of US oncologists have ordered Natera cancer screening tests
- Founded by Matthew Rabinowitz (electrical engineering/physics background, Stanford top student, PhD)
- Co-founded with Jonathan Sheena (2004, mobile startup background)
Genesis Story - Personal Tragedy Drives Innovation
- 2003: Matthew's sister had baby with Down syndrome, died after 6 days
- Hospital only discovered condition at birth despite being top facility
- Matthew couldn't understand how 21st century technology hadn't reached diagnostics
- Mission-driven from start: apply signal processing to genetics
- 2009: Matthew lost second child to genetic condition, screening tests failed to detect
- Used sample from that pregnancy for NIH grant submissions
- Entirely emotional decision to pursue prenatal testing
- "This just broke me... engineering me took over... problem I have to solve"
Early Technology Development - Spectrum Test
- Initial focus: IVF pre-implantation testing market
- Existing methods: crude, only tested 5 of 22 chromosomes
- Natera's breakthrough: Bayesian optimization framework using parental DNA
- Key insight: limit search space using mom/dad genetic data vs. universe of possibilities
- Challenge: single cell analysis from embryo biopsy, extremely noisy data
- Spectrum test: first to use probabilistic modeling of embryo genome from parents
- 2009: Spectrum launched for public use
Early Struggles & Market Reality
- IVF market limitations: ~150,000 cycles/year in US
- Even full market penetration = ~$600M total addressable market
- Early volumes: 100-105 tests/month in 2010
- Board concerns when volume dropped to 90 tests
- Steve Chapman (CEO) thought he might be fired after 3 months
- Funding challenges: Silicon Valley skeptical of genetics, non-geneticists questioned
- Mission-driven approach: "don't worry about funding when you have mission"
Pivot to Prenatal Testing - Panorama
- Natural pregnancies: much larger market than IVF
- Existing prenatal testing (from 1980s): 20% of genetic abnormalities missed
- 19 out of 20 positive results were false positives
- Panorama technology: cell-free fetal DNA from mother's blood at 9 weeks
- Similar signal processing challenge: extract fetal DNA from maternal blood
- Fourth to market (2013) behind Illumina, Roche, Sequenom
- Competitors had 2-year head start, established sales teams
Competitive Challenges & Differentiation
- Illumina acquired main competitor Verinata during Natera's fundraising
- Matthew "curled up in fetal position literally shaking" over supplier/competitor conflict
- Natera's advantages:
- Could separate maternal, paternal, fetal DNA informatically
- Detected microdeletions using deep learning neural networks
- Better user experience (tracking, communication vs. "dark dingy draw stations")
- Decision to offer test to all pregnancies vs. just high-risk (15% → 100% of market)
Rapid Growth & Scaling Challenges
- July 2015: IPO
- Processing over 1 million samples/year for Panorama alone
- Massive hiring: "stacking engineers on top of each other"
- Constant office expansion: "drinking from fire hose"
- Steve Chapman: "literally stacking Engineers on top of each other"
- Sarah Elliot: "onslaught of open positions, interviews, challenge finding top engineering talent"
Oncology Expansion Decision
- Core technology applicable: cancer DNA sheds into bloodstream like fetal DNA
- Massively multiplexed PCR protocol: all primers in single reaction
- Personalized assays based on patient's specific tumor mutations
- Capability: detect single cancer molecule in blood ("one blade of grass in 100,000 soccer fields")
- Signatera test: cancer recurrence monitoring
Major Business Risk & Criticism
- Women's Health not yet profitable when expanding to oncology
- Burning cash, no full Panorama reimbursement
- Stock dropped to $7/share, stayed there ~3 years
- Investor criticism: "abandon oncology, focus on women's health"
- Public investors "repeatedly called and implored" to abandon oncology
- Some analysts/investors "got really frustrated" in meetings
- Employee demoralization: "is the company going to make it?"
Perseverance & Mission Focus
- Core team stayed mission-focused despite $7 stock price
- Lost some employees but core believers remained
- Unified vision across business units, strong collaboration
- Resource constraints drove innovation: "how do we do it differently with fewer resources"
- Matthew's philosophy: "bless the obstacle... put faith in science"
Current Success Metrics
- 2024: ~$1.5B revenue projected
- Stock price: $7 → over $100
- Panorama: most widely used prenatal test in America
- 55-60% of US women's health genetic testing market share
- Oncology: ~50% of US oncologists using Signatera
- Q1 2024: 100,000+ Signatera samples processed (vs. few thousand in 2019)
- Reimbursement: bladder, colon, breast, ovarian cancers
- 7-year cancer survivor example (Jonathan Sheena's mother)
Future Vision & AI Integration
- Order of magnitude growth potential ahead
- Large language models for clinical data curation
- AI modeling for disease susceptibility
- Maintain innovation pace to preserve market leadership
- Mission walls: family photos from customers thanking Natera
- Philosophy: "hard creates value and barriers to others"
